Regulation of plasma erythropoietin in chronic liver disease

Frank Tacke, Tom Luedde, Michael P. Manns, Christian Trautwein

Frank Tacke, Tom Luedde, Michael P. Manns, Christian Trautwein, Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School 30625 Hannover, Germany

Correspondence to: Christian Trautwein, M.D., Professor of Medicine, Hannover Medical School, Department of Gastroenterology, Hepatology and Endocrinology, Carl-Neuberg-Strasse 1, D-30625, Hannover, Germany. trautwein.christian@mh-hannover.de

Received: 2004-05-25 Accepted: 2004-06-22

Tacke F, Luedde T, Manns MP, Trautwein C. Regulation of plasma erythropoietin in chronic liver disease. World J Gastroenterol 2004; 10(19): 2922
http://www.wjgnet.com/1007-9327/10/2922.asp

To the Editor:

In a May-issue of the World Journal of Gastroenterology, there is a very interesting study by Bruno et al. on erythropoietin (EPO) levels in patients with chronic liver disease[1]. We have very recently reported a similar, but much larger study by Tacke et al[2] on the role of EPO in chronic liver disease. By comparing Bruno’s results with our patient cohort and applying their criteria in a re-evaluation of our study population, we uncovered interesting differences between the two studies and could answer some of the key questions in the article raised by Bruno et al., e.g. on the correlation of EPO with liver dysfunction and potential regulating factors in the clinical setting of liver cirrhosis.

Therefore, we would like to briefly present our data and compare the results with Bruno’s recent study. We think the role of EPO is important in the pathophysiology of chronic liver disease, and the recent studies provided new insights into its regulation in liver cirrhosis. Chronic anemia is a common clinical complication in patients with liver cirrhosis and is regarded as an important prognostic factor[3]. The great progress in the understanding of cytokine alterations in chronic liver diseases as well as the discovery and clinical application of different hematopoietic growth factors have raised attention to the potential pathophysiological role of erythropoietin (EPO) in liver diseases[4]. In a recent issue of the World Journal of Gastroenterology, Bruno et al. reported that increased EPO plasma levels were only detected in cirrhotic patients with hemoglobin concentrations below 12 g/dL, and that this EPO response was inadequate compared to patients with iron-deficiency anemia[5]. Furthermore, the authors did not observe an association between EPO levels and the stage of liver cirrhosis or liver synthesis function. The regulating factors in the pathophysiological setting of advanced liver diseases as well as possible clinical consequences remained an open question.

We analyzed 111 patients with chronic liver diseases who were evaluated for potential liver transplantation and 220 healthy (non-anemic) controls with the same EPO ELISA (R&D Systems, Wiesbaden, Germany) kit. In contrast to Bruno et al. who studied mainly patients with viral hepatitis and advanced stages of cirrhosis, our much larger cohort comprised all Child’s stages of cirrhosis in a fairly equal number of patients as well as different etiology subgroups. As we reported recently, EPO plasma levels clearly increased with Child’s stage of liver cirrhosis, independent of the disease etiology (Figure 1)[2]. EPO also correlated directly with the markers of liver synthesis function, e.g. cholinesterase activity \( r = -0.448, P < 0.001 \), albumin concentration \( r = -0.358, P < 0.001 \), or prothrombin time \( r = 0.300, P = 0.001 \). Interestingly, the absolute values of measured EPO levels in Bruno et al. and our studies were relatively similar (e.g. mean EPO 11.6 U/L for chronic hepatitis by Bruno et al., median EPO 11.3 U/L for our “non cirrhosis” group), thereby raising the question whether the clear association between EPO and stage of liver cirrhosis could have been observed if the number of patients included in Bruno et al. study was high enough. Furthermore, it is hard to believe that EPO was normally distributed in anemic or non-anemic cirrhotic patients as the mean±SD values suggested by Bruno et al., thus a different statistical analysis using median and U-test could possibly uncover these important correlations.

We also found a significant inverse correlation between EPO levels and hemoglobin in patients with chronic liver diseases \( r = -0.498, P < 0.001 \), Spearman rank correlation analysis. As this was described by Bruno et al. only for patients with iron-deficiency anemia, this correlation could not be observed when we divided our liver disease patient group by the criteria of Bruno et al. into so-called anemic or non-anemic patients (hb<120 g/L, n=63). However, in accordance with Bruno et al., we also found significantly elevated EPO levels in anemic vs non-anemic liver disease patients (median EPO 29.3 vs 11.4 U/L, \( P < 0.001 \), U-test). In contrast, the non-anemic liver disease patients also had elevated EPO levels as compared with controls \( P < 0.05 \), which could be possibly explained by the much larger control group in our study.

In further investigating the potential regulating factors, one should consider the complex clinical picture of advanced liver cirrhosis. As we could show, the degrees of anemia and liver dysfunction not only were independent parameters associated with elevated EPO in chronic liver disease, but also impaired pulmonary function[4]. Changes in pulmonary function test and blood gas analysis were commonly found in our study population, and EPO was inversely correlated with carbon dioxide tension (pCO₂) and elevated in patients with reduced (carbon monoxide) diffusion capacity. In addition, we noticed a positive correlation between interleukin-6 and EPO, thereby possibly linking the EPO response to a common protective cytokine response usually seen in liver cirrhosis[6].

In conclusion, the recent studies by Bruno et al. and our group provide some new important insights in the regulation of plasma EPO in chronic liver diseases. EPO plasma levels are apparently upregulated in patients with liver cirrhosis, and one might speculate whether this increase is sufficient in the setting of chronic anemia when compared with other forms of anemia.

Figure 1 Erythropoietin plasma levels and stage of cirrhosis. EPO was significantly higher in patients with liver cirrhosis than in healthy controls and increased with Child’s stages of cirrhosis.
e.g. iron-deficiency. However, the regulation of plasma EPO is complex and multifactorial, and the degrees of anemia, liver dysfunction, impaired pulmonary function and cytokine alterations are the major factors in regulating plasma erythropoietin levels in patients with chronic liver diseases.

REFERENCES

1 Bruno CM, Neri S, Sciacca C, Bertino G, Di Prima P, Cilio D, Pellicano R, Caruso L, Cristaldi R. Plasma erythropoietin levels in anaemic and non-anaemic patients with chronic liver diseases. World J Gastroenterol 2004; 10: 1353-1356
2 Tacke F, Schoffski P, Luedde T, Meier PN, Ganser A, Manns MP, Trautwein C. Analysis of factors contributing to higher erythropoietin levels in patients with chronic liver disease. Scand J Gastroenterol 2004; 39: 259-266
3 Orrego H, Israël Y, Blake JE, Medline A. Assessment of prognostic factors in alcoholic liver disease: toward a global quantitative expression of severity. Hepatology 1983; 3: 896-905
4 Pirisi M, Fabris C, Falletti E, Soardo G, Toniutti P, Gorano F, Bartoli E. Evidence for a multifactorial control of serum erythropoietin concentration in liver disease. Clin Chim Acta 1993; 219: 47-55
5 Yang YY, Lin HC, Lee WC, Huang YT, Hou MC, Lee FY, Chang FY, Lee SD. Plasma erythropoietin level in patients with cirrhosis and its relationship to the severity of cirrhosis and renal function. J Gastroenterol Hepatol 2003; 18: 1156-1161
6 Streetz KL, Tacke F, Leifeld L, Wustefeld T, Graw A, Klein C, Camino K, Spengler U, Kreipe H, Kubicka S, Muller W, Manns MP, Trautwein C. Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology 2003; 38: 218-229

Comment on “Eosinophilic gastroenteritis: Clinical experience with 15 patients”

Peter J Kerr

Peter J Kerr, BEng (Hons) CEng, MIEE, MIMechE
Correspondence to: Mr Peter J Kerr, 6 Middledyke Lane, Cottingham, East Yorkshire, HU16 4NH, United Kingdom. pkerr@pkerr.karoo.co.uk
Telephone: +44-1482-847201 Fax: +44-1482-847201
Received: 2004-06-15 Accepted: 2004-06-22

Kerr PJ. Comment on "Eosinophilic gastroenteritis: Clinical experience with 15 patients". World J Gastroenterol 2004; 10(19): 2923
http://www.wjgnet.com/1007-9327/10/2923.asp

To the Editor:

I recently read the paper by Chen et al. [1] published in your Journal. The paper shows that there have been a few cases where medications have caused eosinophilia. Clozapine is an antipsychotic medication that can cause eosinophilia. It is pointed out in your paper “The diagnostic criteria included . . . 5), exclusion of intestinal lymphoma, Crohn’s disease or other tumors.” Table 2 shows symptoms associated with eosinophilic gastroenteritis, which are very like those in Crohn’s disease.

Miss Z, a 29 years old female received a diagnosis of Crohn’s disease five years ago. It seemed to be the more aggressive fistulizing form of Crohn’s disease. The inflammation seemed to be located in her colon. She had several perianal abscesses. Miss Z took the antipsychotic, clozapine. Clozapine can cause constipation, diarrhea [2], nausea [3-8], vomiting [9,10], allergic reactions, etc. Clozapine has also been linked with colitis [11,12], gastrointestinal symptoms [13,14], hepatotoxicity [15,16], eosinophilia [17,18], neutropenia [19,20], colon perforation [21], necrotizing colitis [22], perianal abscesses [23], and increased levels of TNF-alpha [24,25], etc.

When Miss Z was growing up, she had no prodromal symptoms that, even with the benefit of hindsight one might be able to say, this was the beginning of Crohn’s disease. The sickness and diarrhea started 32 days after the clozapine was titrated to its full dose of 300 mg/d in November 1998.

Tumor necrosis factor α (TNF α) is a proinflammatory cytokine that has an important role in the pathogenesis of Crohn’s disease. Infliximab—a chimeric anti-TNF α monoclonal antibody binds to TNF α with high affinity, thereby neutralising its biological activity. Pollmacher et al. [25], found that clozapine significantly increased the plasma levels of TNF-alpha.

Miss Z responded very well to infliximab. Steroids (prednisolone) had little effect on the symptoms. Stopping clozapine was not an option unless we were to be reasonably sure that it was responsible for causing or exacerbating the inflammation in Miss Z’s colon.

I am particularly interested in the effect of clozapine. If it were to cause eosinophilia it might have effects on the colon. I wondered if the symptoms of nausea, vomiting, etc. might persist all the time when clozapine was taken.

REFERENCES

1 Chen MJ, Chu CH, Lin SC, Shih SC, Wang TE. Eosinophilic gastroenteritis: Clinical experience with 15 patients. World J Gastroenterol 2003; 9: 2813-2816
2 Harvey RJ, Bullock T, Montgomery SA. Diarrhoea during treatment with clozapine: association with lymphocyte count. BMJ 1992; 305: 810
3 Patterson BD, Jennings JL. Spiking fever and profuse diarrhea with clozapine treatment. American J Psychiatry 1993; 150: 1126
4 Druss BG, Mazure CM. Transient fever and hematologic abnormalities during clozapine use. J Clin Psychopharmacol 1993; 13: 155-156
5 Lucht MJ, Rietschel M. Clozapine-induced eosinophilia: subsequent neutropenia and corresponding allergic mechanisms. J Clin Psychiatry 1998; 59: 195-197
6 Beck DA, Miller DD. Clozapine-associated neutropenic enterocolitis. Ann Clin Psychiatry 1994; 6: 185-188
7 Galletly C, Wilson D, McEwen S. Eosinophilia associated with decreasing neutrophil count in a clozapine treated patient. J Clin Psychiatry 1996; 57: 40-41
8 Maria DD. Clozapine-induced gastrointestinal symptoms. Llorente, Annual Meeting - American Psychiatric Association. New Research Abstracts 1997; 150: 132
9 Amital D, Gross R, Amital H, Zohar I. Coexistence of eosinophilia and agranulocytosis in a clozapine treated patient. British J Psychiatry 1997; 170: 194
10 Pollmacher T, Hinze-Selch D, Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 1996; 16: 403-409
11 John JP, Chengappa KN, Baker RW, Gupta B, Mortimer MT. Assessment of changes in both weight and frequency of use of medications for the treatment of gastrointestinal symptoms among clozapine-treated patients. Ann Clin Psychiatry 1995; 7: 119-125
12 Macfarlane B, Davies S, Mannan K, Sarasm R, Pariente D, Dooley J. Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity. Gastroenterology 1997; 112: 1707-1709
13 Freundreich O, Golf DC. Colon perforation and peritonitis associated with clozapine. J Clin Psychiatry 2000; 61: 950-951
14 Friedberg JW, Frankenburg FR, Burk J, Johnson W. Clozapine-caused eosinophilic colitis. Ann Clin Psychiatry 1995; 7: 97-98

Edited by Xu XQ, Wang XL and Zhang JZ